Effect of perzinfotel and a proprietary phospholipase A2 inhibitor on kinetic gait and subjective lameness scores in dogs with sodium urate-induced synovitis

American Journal of Veterinary Research

Volumn 72, Issue 6, 2011, Pages 757-763

  Budsberg, Steven C ^a   Torres, Bryan T ^a   Zwijnenberg, Raphael J ^b   Eppler, C Mark ^b   Clark, James D ^b   Cathcart, Curtis J ^a   Reynolds, Lisa R ^a   Al Nadaf, Sami ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARPROFEN; PERZINFOTEL; PHOSPHOLIPASE A2 INHIBITOR; URATE;

ANIMAL LAMENESS; ARTICLE; CLINICAL EVALUATION; DOG; GAIT; GROUND REACTION FORCE; KINETICS; PARAMETERS OF MEASUREMENT AND ANALYSIS; PEAK VERTICAL FORCE; SYNOVITIS; TREATMENT RESPONSE; VERTICAL IMPULSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZABICYCLO COMPOUNDS; BLOOD PROTEINS; CARBAZOLES; CROSS-OVER STUDIES; DOG DISEASES; DOGS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GAIT; KINETICS; LAMENESS, ANIMAL; MALE; PHOSPHONIC ACIDS; SYNOVITIS; URIC ACID;

ANIMALIA; CANIS FAMILIARIS;

EID: 79958045179     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.72.6.757     Document Type: Article

References (30)

1. Christie MJ, Connor M, Vaughan CW, et al. Cellular actions of opioids and other analgesics: implications for synergism in pain relief. Clin Exp Pharmacol Physiol 2000;27:520-523.
2. Kushiro T, Wiese AJ, Eppler MC, et al. Effects of perzinfotel on the minimum alveolar concentration of isoflurane in dogs. Am J Vet Res 2007;68:1294-1299.
3. Pozzi A, Muir WW, Traverso F. Prevention of central sensitization and pain by N-methyl-D-aspartate receptor antagonists. J Am Vet Med Assoc 2006;228:53-60.
4. Lamont LA. Multimodal pain management in veterinary medicine: the physiologic basis of pharmacologic therapies. Vet Clin North Am Small Anim Pract 2008;38:1173-1186.
5. Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 2005;312:726-732.
6. Punke JP, Speas AL, Reynolds LR, et al. Kinetic gait and subjective analysis of the effects of a tachykinin receptor antagonist in dogs with sodium urate-induced synovitis. Am J Vet Res 2007;68:704-708.
7. Hong SK, Han JS, Min SS, et al. Local neurokinin-1 receptor in the knee joint contributes to the induction, but not maintenance, of arthritic pain in the rat. Neurosci Lett 2002;322:21-24.
8. Cui M, Honore P, Zhong C, et al. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci 2006;26:9385-9393.
9. Liu DL, Wang WT, Xing JL, et al. Research progress in transient receptor potential vanilloid 1 of sensory nervous system. Neurosci Bull 2009;25:221-227.
10. McCrory CR, Lindahl SG. Cyclooxygenase inhibition for postoperative analgesia. Anesth Analg 2002;95:169-176.
11. Brandt MR, Cummons TA, Potestio L, et al. Effects of the Nmethyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl] phosphonic acid] on chemically induced thermal hypersensitivity. J Pharmacol Exp Ther 2005;313:1379-1386.
12. Hamilton SM, Johnston SA, Broadstone RV. Evaluation of analgesia provided by the administration of epidural ketamine in dogs with a chemically induced synovitis. Vet Anaesth Analg 2005;32:30-39.
13. Liu H, Mantyh PW, Basbaum AI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature 1997;386:721-724.
14. Miki K, Zhou QQ, Guo W, et al. Changes in gene expression and neuronal phenotype in brain stem pain modulatory circuitry after inflammation. J Neurophysiol 2002;87:750-760.
15. Ueyama Y, Lerche P, Eppler CM, et al. Effects of perzinfotel, fentanyl, and a perzinfotel:fentanyl combination on the minimum alveolar concentration of isoflurane in dogs. Am J Vet Res 2009;70:1459-1464.
16. Marvizon JC, McRoberts JA, Ennes HS, et al. Two N-methyl-D-aspartate receptors in rat dorsal root ganglia with different subunit composition and localization. J Comp Neurol 2002;446:325-341.
17. Kudoh A, Takahira Y, Katagai H, et al. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002;95:114-118.
18. Farooqui AA, Ong WY, Horrocks LA. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 2006;58:591-620.
19. Yaksh TL, Kokotos G, Svensson CI, et al. Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin E2 release. J Pharmacol Exp Ther 2006;316:466-475.
20. Petrenko AB, Yamakura T, Baba H, et al. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003;97:1108-1116.
21. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 2009;50(suppl):S237-S242.
22. Balsinde J, Winstead MV, Dennis EA. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett 2002;531:2-6.
23. Bergh MS, Budsberg SC. The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 2005;19:633-643.
24. Fitzpatrick FA SR. Regulated formation of eicosanoids. J Clin Invest 2001;107:1347-1351.
25. Svensson CI, Yaksh TL. The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 2002;42:553-583.
26. Cross AR, Budsberg SC, Keefe TJ. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. Am J Vet Res 1997;58:626-631.
27. Millis DL, Weigel JP, Moyers T, et al. Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. Vet Ther 2002;3:453-464.
28. Farooqui AA, Horrocks LA. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 2006;12:245-260.
29. Adler DH, Cogan JD, Phillips JA, et al. Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest 2008;118:2121-2131.
30. Vaughan CW, Ingram SL, Connor MA, et al. How opioids inhibit GABA-mediated neurotransmission. Nature 1997;390:611-614.